Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles.
A compendium of hepatic gene expression signatures was used to identify a mechanistic basis for the hepatic toxicity of an experimental CCR5 antagonist (MrkA). Development of MrkA, a potential HIV therapeutic, was discontinued due to hepatotoxicity in preclinical studies. Rats were treated with MrkA at 3 dose levels (50, 250, and 500 mg/kg) for 1, 3, or 7 days. Hepatic toxicity (vacuolation, consistent with steatosis, and elevated serum transaminase levels) was observed at 250 and 500 mg/kg, but not at 50 mg/kg. Hepatic gene expression profiles were compared to a compendium of hepatic expression profiles. MrkA was similar to 3 beta-oxidation inhibitors (valproate, cyclopropane carboxylate, pivalate), 8 PPARalpha agonists (fenofibrate, bezafibrate and 6 fibrate analogues), and 3 other diverse compounds (diethylnitrosamine, microcystin LR & actinomycin D). These data indicate MrkA to be a mitochondrial inhibitor, and activation of PPARalpha-regulated transcription was thought to be due to an accumulation of endogenous ligands. While mitochondrial inhibition was likely responsible for steatosis, canonical pathway analysis revealed that progression to liver injury may be mediated by activation of the innate immune system primarily through NF-kB pathways. These results demonstrate the utility of a gene expression response compendium in developing transcriptional biomarkers and identifying the mechanistic basis for toxicity.
Cornwell
Paul D
PD
Rosetta Inpharmatics LLC (A wholly owned subsidiary of Merck & Co., Inc.), Seattle, WA 98109, USA. CornwellPD@lilly.com
Ulrich
Roger G
RG
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D065100:CCR5 Receptor Antagonists; D056486:Chemical and Drug Induced Liver Injury / Q000235:genetics* / Q000473:pathology*; D030541:Databases, Genetic; D018628:Gene Dosage; D015870:Gene Expression / Q000187:drug effects; D020869:Gene Expression Profiling; D008297:Male; D008930:Mitochondria, Liver / Q000187:drug effects / Q000473:pathology; D016612:Paraffin Embedding; D011720:Pyrazoles / Q000633:toxicity*; D012313:RNA / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D014633:Valine / Q000031:analogs & derivatives* / Q000633:toxicity
C473211:2-(N-methyl-N-(((4-(3-benzyl-1-ethyl-(1H)-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)cyclopent-1-yl)amino)-3-methylbutanoic acid; D065100:CCR5 Receptor Antagonists; D011720:Pyrazoles; D012313:RNA; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D014633:Valine